Upcoming Mega Pharmaceutical Project in Uttar Pradesh — featuring advanced Biosimilars and Monoclonal Antibodies (mAbs) capabilities || Integrated Pharmaceuticals Excellence — From R&D, APIs & Formulations to Biosimilars & mAbs
Career Enquiry:
+91-7807836763
Business Enquiry:
+91-7807096343
biozenta@gmail.com
Home
Company Profile
Vision and Mission
About Us
Management & Leadership
Business Value
Vision 2030
Infrastructure
Manufacturing
Packaging
R & D
API Development
Quality Control
Accreditations
Products
Biozenta Formulation
Biozenta Ethicaz
Oncology
Liquid Injection
Lyophilized
PFS
Tablets
Capsules
General
Injection
Lyophilized
PFS
Contrast Media
Tablets
Capsules
Biozenta Genericaz
Biozenta API
API List
INT List
Biozenta Farmacia
Liquid Injectables
Lyophilized Injectables
Tablets
Capsules
Global Presence
Services
Manufacturing Support
Institutional Tenders
Regulatory Service
Why us?
Events
Texfer
Career
Contact Us
Request A Call Back
Submit
Register Drug Shortage
Online Enquiry
Job Opportunities
Contrast Media
Home
Contrast Media
CAPSULES PRODUCTS
Iohexol Injection USP 300 mg
Iohexol Injection USP 350 mg
Iopamidol Injection USP 61.0 % w/v, 300 mg
Iopamidol Injection USP 70.0 % w/v, 340 mg
Iopamidol Injection USP 76.0 % w/v, 370 mg
Gadodiamide Injection USP 387 mg
Ioversol Injection USP 74.0% w/v, 350 mg
Ioversol Injection USP 68.0% w/v, 320 mg
Ioversol Injection USP 64.0% w/v, 300 mg
Ioversol Injection USP 51.0% w/v, 240 mg
Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 76 %
